messag report rev/ep slightli ahead consensu
takeaway call includ ingrezza inhibitor approv tardiv
dyskinesia sale good came ahead consensu expect
better growth typic season strong orilissa gnrh antagonist
launch track compani expect slower-than-expect
uptak though manag note still hold posit l-t outlook
drug expect global pivot trial begin model updat
reflect current trend reiter neutral rate increas pt
perform ingrezza see continu growth throughout rest
year
ingrezza sale slightli ahead consensu ingrezza sale came
q/q y/i beat consensu though come slightli
estim increment q/q script growth decent
moder lower quarter averag net revenu
per script drop slightli quarter howev
manag note quarter perform benefit lower-than-expect
headwind record number new patient initi treatment partial driven
expand sale team unbrand awar campaign partial off-set
slightli lower script refil rate vs bit lower revenu per script
believ sale could assum net increment q/q script
growth patient tend stronger quarter averag script
growth script increment q/q revenu increas
per script get impli sale
orilissa uptak continu disappoint though still posit drug
report previous orilissa sale came vs impli
consensu sale translat
royalti comment orilissa call last week
manag note meet latter acknowledg
launch go slower anticip assess adjust barrier
orilissa market creation difficulti includ low obgyn experi prior
author women see ob per year thu lower frequenc
prescrib drug affect women
ingrezza chorea associ huntington compani expect phase
kinect-hd trial ingrezza chorea huntington diseas common
involuntari movement problem huntington begin enrol patient shortli
could data view nice potenti increment expans
opportun ingrezza though view potenti address popul like
fairli limit least initi huntington patient chorea
moderate-to-sever treat suggest initi address
gene therapi program voyag continu advanc phase ii
vy-aadc gene therapi program engag fda order
get feedback registr trial design addit continu work
page analyst certif import disclosur
voyag advanc three gene therapi program friedreich ataxia two
unnam indic toward clinic
receptor antagonist adult pediatr phase ii trial
on-going manag alreadi held discuss fda regard pivot
trial design current review plan ex-u regul goal
initi global registr adult trial
financi report total revenu q/q vs
consensu estim respect ingrezza sale
q/q vs consensu estim
respect orilissa royalti vs consensu estim
respect dilut ep came vs consensu
estim respect end cash
model updat reflect chang expect futur perform
current trend adjust revenu estim
respect non-gaap ep estim
respect base
chang also increas npv-deriv sum-of-th part sotp pt
page analyst certif import disclosur
guggenheim secur llc research compani report
page analyst certif import disclosur
agentindicationtrialpotenti catalysttimingstock inhibitor valbenazin chorea associ huntington sphase top-line data kinect-hd inhibitor parkinson diseasen/apdufa dateapril antagonist cahpivot phase adult initi trial pend fda discussionmid iitoplin data adult initi pivot trialmid voyag parkinson diseasephas idur diseasephas iitoplin dataest diseasephas final registr plan novel compoundmultipl disordersphas iiniti gnrh antagonist uterin fibroidsn/apdufa
guggenheim secur llc research compani report
pt increas base sum-of-the-part sotp net-present-valu npv
includ probability-adjust npv ingrezza sale orilissa royalti opicapon sale technolog
valu compani anticip net cash posit
use discount rate termin valu believ appropri similar stage compani
upsid risk includ ingrezza and/or orilissa sale grow faster expect approv indic
downsid risk includ regulatori commerci setback potenti emerg new competitor
page analyst certif import disclosur
productsnpv mm probabl successnpv per cash outstand basic outstand fulli dilut includ share convert sum-of-th part sotp npv
page analyst certif import disclosur
qoq licens incom expens incom tax rate incom cash flow capit rais compani report guggenheim secur llc estim mm yatin suneja
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc financi advisor inc strateg collabor inc
guggenheim secur llc affili expect receiv intend seek compens invest bank servic neurocrin
bioscienc inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori inc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
